外显子组测序作为胎儿严重中枢神经系统结构异常的一线检测
该回顾性研究纳入114例因产前超声发现严重中枢神经系统异常而终止妊娠的胎儿,所有胎儿先行染色体微阵列分析(CMA),CMA阴性者行外显子组测序(ES)。CMA检出致病/可能致病拷贝数变异11/114(10%),86例CMA阴性者中ES检出致病/可能致病序列变异38/86(44%);ES对10例CMA阳性病例再分析亦检出全部致病/可能致病拷贝数变异。作者认为ES可作为胎儿严重中枢神经系统异常产前诊断的一线检测。
要点
- CMA在114例中检出致病/可能致病拷贝数变异11例(10%)。
- CMA阴性者中ES检出致病/可能致病序列变异38/86(44%)。
- ES流程对10例CMA阳性病例再分析检出全部致病/可能致病拷贝数变异。
核心结论
- ES在严重胎儿中枢神经系统结构异常中诊断率高(>50%),可考虑作为产前诊断的一线检测,同时检测致病/可能致病序列变异和拷贝数变异。
研究设计与样本
- 回顾性研究,纳入114例因产前超声发现严重中枢神经系统异常而终止妊娠后转诊行遗传评估的病例;所有胎儿先行CMA,CMA阴性者行ES,CMA阳性者用ES再分析以评估拷贝数变异检测能力。
诊断标准与关键数值
- CMA在114例中检出致病/可能致病拷贝数变异11/114(10%)。
- 86例CMA阴性者中ES检出致病/可能致病序列变异38/86(44%)。
- 复发型病例(既往有受累妊娠)中致病/可能致病序列变异发生率12/19(63%) vs 非复发型26/67(39%),P=0.06,差异未达统计学显著。
- 38例ES诊断病例中20例(53%)为遗传性,携带显著复发风险。
- 10例CMA阳性病例经ES再分析,序列变异分析流程检出全部致病/可能致病拷贝数变异及3个既往已知非致病性拷贝数变异。
临床应用与阅片要点
- 作者认为,ES可考虑作为胎儿严重中枢神经系统异常产前诊断的一线检测。
- 作者指出,鉴于持续妊娠的时间限制及未来妊娠的复发风险,ES同时检测序列变异和拷贝数变异尤为重要。
局限性
- 作者指出,ES诊断率>50%可能部分源于高度选择的病例系列,包括来自专科转诊中心的终止妊娠后病例。
- 研究为回顾性研究。
- 作者结论使用「may be considered」表示ES可考虑作为一线检测,而非确定性推荐。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: Prenatally detected central nervous system (CNS) anomalies present a diagnostic challenge. In this study, we compared the diagnostic yield of exome sequencing (ES) and chromosomal microarray analysis (CMA) in fetuses with a major CNS anomaly.
METHODS: This was a retrospective study of 114 cases referred for genetic evaluation following termination of pregnancy (TOP) due to a major CNS anomaly detected on prenatal ultrasound. All fetuses were first analyzed by CMA. All CMA-negative cases were offered ES. CMA-positive cases were reanalyzed using ES to assess its ability to detect copy-number variants (CNVs).
RESULTS: CMA identified a pathogenic or likely pathogenic (P/LP) CNV in 11/114 (10%) cases. Eighty-six CMA-negative cases were analyzed using ES, which detected P/LP sequence variants in 38/86 (44%). Among recurrent cases (i.e. cases with a previously affected pregnancy), the incidence of P/LP sequence variants was non-significantly higher compared with non-recurrent ones (12/19 (63%) vs 26/67 (39%); P = 0.06). Among the 38 cases with an ES diagnosis, 20 (53%) were inherited and carried a significant risk of recurrence. Reanalysis of 10 CMA-positive cases by ES demonstrated that the bioinformatics pipeline used for sequence variant analysis also detected all P/LP CNVs, as well as three previously known non-causative CNVs.
CONCLUSIONS: In our study, ES provided a high diagnostic yield (> 50%) in fetuses with severe CNS structural anomalies, which may have been partly due to the highly selected case series that included post-TOP cases from a specialist referral center. These data suggest that ES may be considered as a first-tier test for the prenatal diagnosis of major fetal CNS anomalies, detecting both P/LP sequence variants and CNVs. This is of particular importance given the time constraints of an ongoing pregnancy and the risk of recurrence in future pregnancies. © 2022 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Yaron Y, Ofen Glassner V, Mory A, et al. Exome sequencing as first-tier test for fetuses with severe central nervous system structural anomalies. Ultrasound Obstet Gynecol. 2022. PMID: 35229910. doi:10.1002/uog.24885
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。